Efficacy and Tolerability of Tebentafusp in Metastatic Uveal Melanoma: A Real-life Retrospective Multicentre Study
Metastatic uveal melanoma is a rare disease with a poor prognosis. Usual treatments have not proven effective. Tebentafusp, a bispecific protein targeting melanoma cells and T lymphocytes, is the first approved treatment with a proven survival benefit in a randomized clinical. Our purpose was to evaluate tebentafusp's real-life efficacy and tolerability for metastatic uveal melanoma. This retrospective study included patients from 14 French centres. Twenty-three patients were included. One-year survival was 66%; median progression-free survival was 5.7 months. Objective response rate was 23% and best overall response was complete remission for 4% of patients; partial remission for 18%, stable disease for 41%, and progressive disease for 36%. The most frequent adverse events were fever, chills, pruritus, and rash; 30% experienced severe adverse events. No death or treatment discontinuation was linked to adverse events. These data showed better overall survival with tebentafusp than that reported in historical cohorts.
Authors
- L. Vitek
- J.-M. L’Orphelin (ORCID: https://orcid.org/0000-0002-5680-7888)
- A. Lamoureux
- Thomas Goronflot (ORCID: https://orcid.org/0000-0002-1019-9821)
- Anne-Bénédicte Duval-Modeste
- G. Jeudy (ORCID: https://orcid.org/0009-0003-7065-9097)
- Caroline Gaudy‐Marqueste (ORCID: https://orcid.org/0000-0001-6955-5117)
- Délphine Legoupil (ORCID: https://orcid.org/0000-0002-1194-7668)
- Caroline Dutriaux (ORCID: https://orcid.org/0000-0002-9836-5168)
- L. Peuvrel (ORCID: https://orcid.org/0000-0002-4347-915X)
- Amir Khammari
- Yannick Le Corre (ORCID: https://orcid.org/0000-0003-3089-3068)
- Antoine Deleuze (ORCID: https://orcid.org/0000-0003-4635-0092)
- Laurent Mortier (ORCID: https://orcid.org/0000-0002-2644-1790)
- Barouyr Baroudjian (ORCID: https://orcid.org/0000-0003-4703-8340)
- Gaelle Quereux (ORCID: https://orcid.org/0000-0002-1739-1701)
- Cécile Fresnard
Institutions
- Inserm (FR)
- Aix-Marseille Université (FR)
- Centre Hospitalier Universitaire de Lille (FR)
- Centre Hospitalier Universitaire de Nantes (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Institut de Cancérologie de l'Ouest (FR)
- Centre Eugène Marquis (FR)
- Hôpital Saint-André (FR)
- Centre Hospitalier Universitaire d'Angers (FR)
- Centre Hospitalier Universitaire de Caen Normandie (FR)
- Centre Hospitalier Régional Universitaire de Brest (FR)
- Centre Hospitalier de La Rochelle (FR)
- Hôpital Saint Eloi (FR)
- Hôpital Saint-Louis (FR)
- Université de Rouen Normandie (FR)
- Université de Caen Normandie (FR)
Publication Details
- Journal
- Acta Dermato Venereologica
- Published
- 2024-12-12
- DOI
- https://doi.org/10.2340/actadv.v104.41297
- Citations
- 8
- Primary Topic
- Ocular Oncology and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 4.31
Funders
- Société Française de Dermatologie et de Pathologie Sexuellement Transmissible